0NWK Stock Overview
A clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Valerio Therapeutics Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.086 |
| 52 Week High | €0.17 |
| 52 Week Low | €0.086 |
| Beta | 1.72 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -84.89% |
| Change since IPO | -99.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0NWK | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.0% | 1.7% |
| 1Y | n/a | -17.5% | 8.3% |
Return vs Industry: Insufficient data to determine how 0NWK performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0NWK performed against the UK Market.
Price Volatility
| 0NWK volatility | |
|---|---|
| 0NWK Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0NWK's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0NWK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 38 | Julien Miara | valeriotx.com |
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in Phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer. It also develops Revocan that is in Phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP inhibitor resistance in second-line maintenance treatment of recurrent ovarian cancer, as well as in phase 1b/2 trial evaluating AsiDNA in combination with radiotherapy in recurrent highgrade glioma in children.
Valerio Therapeutics Société anonyme Fundamentals Summary
| 0NWK fundamental statistics | |
|---|---|
| Market cap | €11.87m |
| Earnings (TTM) | -€19.66m |
| Revenue (TTM) | €1.89m |
6.3x
P/S Ratio-0.6x
P/E RatioIs 0NWK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NWK income statement (TTM) | |
|---|---|
| Revenue | €1.89m |
| Cost of Revenue | €477.00k |
| Gross Profit | €1.41m |
| Other Expenses | €21.07m |
| Earnings | -€19.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 74.75% |
| Net Profit Margin | -1,040.66% |
| Debt/Equity Ratio | 317.0% |
How did 0NWK perform over the long term?
See historical performance and comparison